inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: 1. adult male or female patient, aged between 18 to 60 years (both inclusive). 2. patient with laboratory confirmed sars-cov-2 infection by reverse transcription polymerase chain reaction (rt-pcr) at screening. 3. patient has mild conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. 4. onset of symptom is no more than 7 days prior to the study drug administration.

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: 1. adult male or female patient, aged between 18 to 60 years (both inclusive). 2. patient with laboratory confirmed sars-cov-2 infection by reverse transcription polymerase chain reaction (rt-pcr) at screening. 3. patient has mild conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. 4. onset of symptom is no more than 7 days prior to the study drug administration.

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: adult male or female patient, aged between 18 to 60 years (both inclusive). patient with laboratory confirmed sars-cov-2 infection by reverse transcription polymerase chain reaction (rt-pcr) at screening. patient has mild conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. onset of symptom is no more than 7 days prior to the study drug administration.

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: adult male or female patient, aged between 18 to 60 years (both inclusive). patient with laboratory confirmed sars-cov-2 infection by reverse transcription polymerase chain reaction (rt-pcr) at screening. patient has mild conditions meeting all of the following criteria: oxygen saturation ≥ 94% on room air. not requiring supplemental oxygen. onset of symptom is no more than 7 days prior to the study drug administration.

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: 1. adult male or female patient, aged between 18 to 60 years (both inclusive). 2. patient with laboratory confirmed sars-cov-2 infection by reverse transcription polymerase chain reaction (rt-pcr) at screening. 3. patient has mild conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. 4. onset of symptom is no more than 7 days prior to the study drug administration.

inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: 1. adult male or female patient, aged between 18 to 60 years (both inclusive). 2. patient with laboratory confirmed sars-cov-2 infection by reverse transcription polymerase chain reaction (rt-pcr) at screening. 3. patient has mild conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. 4. onset of symptom is no more than 7 days prior to the study drug administration.